These findings indicate that ZNF582 and PAX1 methylation in cancer-adjacent normal tissue, as well as cancer sites, are potential biomarkers that can help to predict OSCC progression and OSCC patient survival [72]. This evidence concerns the gene ZNF582 and cancer.